- Home
- NXTC vs ATER Comparison
NXTC vs ATER Comparison
Compare NXTC & ATER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- ATER
- Stock Information
- Founded
- NXTC 2015
- ATER 2014
- Country
- NXTC United States
- ATER United States
- Employees
- NXTC N/A
- ATER N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- ATER Home Furnishings
- Sector
- NXTC Health Care
- ATER Consumer Discretionary
- Exchange
- NXTC Nasdaq
- ATER Nasdaq
- Market Cap
- NXTC 13.9M
- ATER 15.5M
- IPO Year
- NXTC 2019
- ATER N/A
- Fundamental
- Price
- NXTC $0.48
- ATER $1.66
- Analyst Decision
- NXTC Strong Buy
- ATER
- Analyst Count
- NXTC 2
- ATER 0
- Target Price
- NXTC $3.50
- ATER N/A
- AVG Volume (30 Days)
- NXTC 336.1K
- ATER 243.8K
- Earning Date
- NXTC 07-31-2025
- ATER 08-07-2025
- Dividend Yield
- NXTC N/A
- ATER N/A
- EPS Growth
- NXTC N/A
- ATER N/A
- EPS
- NXTC N/A
- ATER N/A
- Revenue
- NXTC N/A
- ATER $94,191,000.00
- Revenue This Year
- NXTC N/A
- ATER N/A
- Revenue Next Year
- NXTC N/A
- ATER $7.48
- P/E Ratio
- NXTC N/A
- ATER N/A
- Revenue Growth
- NXTC N/A
- ATER N/A
- 52 Week Low
- NXTC $0.22
- ATER $1.22
- 52 Week High
- NXTC $1.82
- ATER $3.84
- Technical
- Relative Strength Index (RSI)
- NXTC 44.82
- ATER 58.30
- Support Level
- NXTC $0.45
- ATER $1.34
- Resistance Level
- NXTC $0.51
- ATER $1.52
- Average True Range (ATR)
- NXTC 0.07
- ATER 0.13
- MACD
- NXTC -0.01
- ATER 0.05
- Stochastic Oscillator
- NXTC 3.24
- ATER 88.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.